373 related articles for article (PubMed ID: 14684587)
1. Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C.
Thuluvath PJ; Maheshwari A; Mehdi J; Fairbanks KD; Wu LL; Gelrud LG; Ryan MJ; Anania FA; Lobis IF; Black M
Gut; 2004 Jan; 53(1):130-5. PubMed ID: 14684587
[TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
[TBL] [Abstract][Full Text] [Related]
3. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial.
Berg T; Kronenberger B; Hinrichsen H; Gerlach T; Buggisch P; Herrmann E; Spengler U; Goeser T; Nasser S; Wursthorn K; Pape GR; Hopf U; Zeuzem S
Hepatology; 2003 Jun; 37(6):1359-67. PubMed ID: 12774015
[TBL] [Abstract][Full Text] [Related]
4. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
5. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
[TBL] [Abstract][Full Text] [Related]
6. First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C.
Reiser M; Buggisch P; Grossmann J; Koop K; Wursthorn K; Schmiegel W
Eur J Gastroenterol Hepatol; 2003 Dec; 15(12):1299-304. PubMed ID: 14624153
[TBL] [Abstract][Full Text] [Related]
7. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin.
Thuluvath PJ; Pande H; Maygers J
Dig Dis Sci; 2003 Mar; 48(3):594-7. PubMed ID: 12757175
[TBL] [Abstract][Full Text] [Related]
9. Triple combination of interferon alpha-2b, ribavirin, and amantadine for treatment of chronic hepatitis C.
Younossi ZM; Mullen KD; Hodnick S; Barnes DS; Carey WD; McCullough AC; Easley K; Gramlich T; Liebermann BY
J Clin Gastroenterol; 2003; 36(5):427-30. PubMed ID: 12702987
[TBL] [Abstract][Full Text] [Related]
10. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.
Reichard O; Norkrans G; Frydén A; Braconier JH; Sönnerborg A; Weiland O
Lancet; 1998 Jan; 351(9096):83-7. PubMed ID: 9439491
[TBL] [Abstract][Full Text] [Related]
11. Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection.
Engler S; Flechtenmacher C; Wiedemann KH; Gugler R; Stremmel W; Kallinowski B
J Viral Hepat; 2004 Jan; 11(1):60-8. PubMed ID: 14738559
[TBL] [Abstract][Full Text] [Related]
12. Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.
von Wagner M; Hofmann WP; Teuber G; Berg T; Goeser T; Spengler U; Hinrichsen H; Weidenbach H; Gerken G; Manns M; Buggisch P; Herrmann E; Zeuzem S
Hepatology; 2008 Nov; 48(5):1404-11. PubMed ID: 18846541
[TBL] [Abstract][Full Text] [Related]
13. A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients.
Puoti M; Zanini B; Quinzan GP; Ravasio L; Paraninfo G; Santantonio T; Rollo A; Artioli S; Maggiolo F; Zaltron S; Raise E; Mignani E; Resta F; Verucchi G; Pastore G; Suter F; Carosi G;
J Hepatol; 2004 Aug; 41(2):312-8. PubMed ID: 15288482
[TBL] [Abstract][Full Text] [Related]
14. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
[TBL] [Abstract][Full Text] [Related]
15. Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial.
Helbling B; Stamenic I; Viani F; Gonvers JJ; Dufour JF; Reichen J; Cathomas G; Steuerwald M; Borovicka J; Sagmeister M; Renner EL;
Hepatology; 2002 Feb; 35(2):447-54. PubMed ID: 11826422
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial of double versus triple therapy with amantadine for genotype 1 chronic hepatitis C in Latino patients.
Méndez-Navarro J; Chirino RA; Corey KE; Gorospe EC; Zheng H; Morán S; Juarez JA; Chung RT; Dehesa-Violante M
Dig Dis Sci; 2010 Sep; 55(9):2629-35. PubMed ID: 19960257
[TBL] [Abstract][Full Text] [Related]
17. Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C.
Teuber G; Pascu M; Berg T; Lafrenz M; Pausch J; Kullmann F; Ramadori G; Arnold R; Weidenbach H; Musch E; Junge U; Wiedmann KH; Herrmann E; Zankel M; Zeuzem S
J Hepatol; 2003 Oct; 39(4):606-13. PubMed ID: 12971972
[TBL] [Abstract][Full Text] [Related]
18. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
Scotto G; Fazio V; Palumbo E; Cibelli DC; Saracino A; Angarano G
New Microbiol; 2005 Jan; 28(1):23-9. PubMed ID: 15782623
[TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
Lawitz E; Lalezari JP; Hassanein T; Kowdley KV; Poordad FF; Sheikh AM; Afdhal NH; Bernstein DE; Dejesus E; Freilich B; Nelson DR; Dieterich DT; Jacobson IM; Jensen D; Abrams GA; Darling JM; Rodriguez-Torres M; Reddy KR; Sulkowski MS; Bzowej NH; Hyland RH; Mo H; Lin M; Mader M; Hindes R; Albanis E; Symonds WT; Berrey MM; Muir A
Lancet Infect Dis; 2013 May; 13(5):401-8. PubMed ID: 23499158
[TBL] [Abstract][Full Text] [Related]
20. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
McHutchison JG; Gordon SC; Schiff ER; Shiffman ML; Lee WM; Rustgi VK; Goodman ZD; Ling MH; Cort S; Albrecht JK
N Engl J Med; 1998 Nov; 339(21):1485-92. PubMed ID: 9819446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
